IVA vs LKFT
Inventiva S.a. and Lakefront Biotherapeutics NV, side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | IVA | LKFT |
|---|---|---|
| Revenue | €9.2M | €1.1B |
| Net income | €-184.2M | €320.9M |
| Gross margin | · | 97.3% |
| Net margin | · | 28.9% |
| Return on equity | · | 10.5% |
| Diluted EPS | −€3.08 | €4.87 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | €-271.2M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 0.92× | 20.15× |
| Revenue CAGR 5y | 5.6% | 18.4% |
| Profit CAGR 5y | · | · |
LKFT bills 120.9× the revenue of IVA, and IVA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | IVA | LKFT |
|---|---|---|
| FY2024 | €9.2M | €275.6M |
| FY2023 | €17.5M | €239.7M |
| FY2022 | €12.2M | €241.2M |
| FY2021 | €4.2M | €234.4M |
| FY2020 | €372,000 | €478.1M |
| FY2019 | €7.0M | €834.9M |
| FY2018 | €3.2M | €278.7M |
Bottom line
| Fiscal year | IVA | LKFT |
|---|---|---|
| FY2024 | €-184.2M | €74.1M |
| FY2023 | €-110.4M | €211.7M |
| FY2022 | €-54.3M | €-218.0M |
| FY2021 | €-49.6M | €-103.2M |
| FY2020 | €-33.6M | €-305.4M |
| FY2019 | €-30.2M | €149.8M |
| FY2018 | €-33.0M | €-29.3M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −€266,451,000 | LKFT |
| FY2023 | −€222,247,000 | LKFT |
| FY2022 | −€229,070,000 | LKFT |
| FY2021 | −€230,190,000 | LKFT |
| FY2020 | −€477,681,000 | LKFT |
| FY2019 | −€827,903,000 | LKFT |
| FY2018 | −€275,469,000 | LKFT |
LKFT has reported the higher revenue in every one of these 7 fiscal years. The gap has narrowed since the earliest year compared.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2023 | −720.1 pp | LKFT |
| FY2022 | −355.3 pp | LKFT |
| FY2021 | −1139.4 pp | LKFT |
| FY2019 | −449.8 pp | LKFT |
| FY2018 | −1022.2 pp | LKFT |
LKFT has kept the higher net margin in every one of these 5 fiscal years.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IVA's net margin has been more volatile than LKFT's over the 5 comparable fiscal years — 308.4 percentage points of standard deviation against 60.1.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LKFT led in net margin in every one of the 5 comparable fiscal years — a structural lead, not a recent swing.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IVA's return on equity has been more volatile than LKFT's over the 5 comparable fiscal years — 12.7 percentage points of standard deviation against 6.3.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LKFT led in return on equity in every one of the 5 comparable fiscal years — a structural lead, not a recent swing.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.